NeuroQuant Update Includes Tools for Evaluating Cerebral Microhemorrhages

Cortechs.ai announced a major update for its flagship product, NeuroQuant v5.0, which is currently FDA 510(k) pending.

This latest update to NeuroQuant will expand the use of the software to support identification and evaluation of cerebral microhemorrhages on susceptibility-sensitive MRI sequences - small focal brain lesions commonly found in patients with Traumatic Brain Injuries (TBI), Cerebral Amyloid Deposition Diseases including Cerebral Amyloid Angiopathy (CAA) and Alzheimer's Disease (AD), as well as patients with Amyloid Related Imaging Abnormalities (ARIA).

"Our upcoming NeuroQuant v5.0 application empowers healthcare professionals with precise data to inform diagnoses and monitor brain health. This innovation underscores our commitment to advancing neurological care for radiologists, neurologists, researchers, and patients alike." says Brandon Steach, Head of Product at Cortechs.ai.

Nate White, PhD and Chief Technology Officer, says "Since the first commercial launch of NeuroQuant in 2006, Cortechs continues to lead our industry, driving transformation through pioneering initiatives and fueling innovation in imaging-based AI technologies. The release of NeuroQuant v5.0 strengthens our commitment to staying ahead of the curve and continuously pushing boundaries to provide AI-driven solutions to optimize patient care."